Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00980200 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety Study in Subjects With Asthma

A Phase 2 study, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 2
Development phase
75
Enrollment target

NCT00980200: Completed Phase 2 study, sponsored by GlaxoSmithKline.

NCT00980200 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 75 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00980200, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 2
Development phase
75 participants
Enrollment target

Study Summary

The study is a multi-center, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of selected doses and dose intervals of the novel long acting beta agonist (LABA), GW642444 in asthmatic subjects ≥18 years of age who are currently receiving inhaled corticosteroid treatment.

Primary Outcome

Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as the mean of the FEV1 values obtained at the last two scheduled time points at the Day 7 clinic visit (i.e., 11 and 12 hours after the morning dose, or 23 and 24 hours after the evening dose). Change from Baseline was calculated as the Day 7 value minus the Baseline value. Analysis was performed using a mixed

Interventions

  • DRUG placebo
  • DRUG Dose 4 QD
  • DRUG Dose 3 QD
  • DRUG Dose 2 QD
  • DRUG Dose 1 BD

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2009-09
Est. Completion 2010-01
Phase Phase 2
GlaxoSmithKline

1,345 total trials

What the finished NCT00980200 record still lists

NCT00980200 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower).

The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.

NCT00980200 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00980200 about?

NCT00980200 is a clinical study titled "Efficacy and Safety Study in Subjects With Asthma". The study is a multi-center, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of selected doses and dose intervals of the novel long acting beta agonist (LABA), GW642444 in asthmatic subjects ≥18 years of age who are currently receiving inhaled corticosteroid tr...

What is the current status of trial NCT00980200?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2009-09. Estimated completion is 2010-01.

What interventions are being tested in trial NCT00980200?

The interventions under investigation include: placebo (DRUG), Dose 4 QD (DRUG), Dose 3 QD (DRUG), Dose 2 QD (DRUG), Dose 1 BD (DRUG).

Who is sponsoring clinical trial NCT00980200?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00980200's enrollment target sits among peer trials

75 900th of 2000 higher than 1,081 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00980200, the US trial registry maintained by the National Library of Medicine. NCT00980200 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.